U. Y. Fincorp Announces Rs 187.17 Crore Capital Infusion

187.17 crore total fundraise; 24.40 issue price per security.

Reader Takeaway: The capital injection strengthens the balance sheet, but investors must account for equity dilution from new share issuance.

What just happened

U. Y. Fincorp Ltd’s board of directors approved a preferential issue of securities on November 2, 2026. The company intends to raise Rs 187.17 crore through a mix of equity shares and convertible warrants. This move is part of the company’s broader capital raising strategy and requires final approval from shareholders and regulators.

Fundraising Breakdown

The proposal includes the issuance of 5,21,20,000 equity shares at Rs 24.40 each, totaling Rs 127.17 crore. Additionally, the company will issue 2,45,90,000 convertible warrants at the same price, amounting to Rs 59.99 crore. Each warrant is convertible into one equity share within 18 months from the date of allotment.

What this means for shareholders

This capital infusion is expected to provide U. Y. Fincorp with significant growth capital. However, for current shareholders, the issuance of new shares will lead to equity dilution. Investors should watch the upcoming Extraordinary General Meeting (EGM) process closely to understand the full terms and the impact on earnings per share.

What to track next

The immediate focus for stakeholders is the EGM outcome and the timeline for final regulatory approvals under the SEBI (ICDR) Regulations, 2018.